A Multicenter Medical Safety Follow-up Study for Patients With Partial Onset Seizures Who Received More Than 28 Days of Total Exposure to BGG492 in Studies CBGG492A2207 and/or CBGG492A2212
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Selurampanel (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Sponsors Novartis
- 11 Apr 2016 Trial protocol (Primary endpoints,time frame for primary endpoints and treatment ) amended.
- 06 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials. gov.
- 06 Jan 2015 Planned End Date changed from 1 Nov 2014 to 1 Jun 2015, according to ClinicalTrials. gov record.